SMARCB1 rs1060503015: What Your Genotype Means

What each genotype means

Understanding the SMARCB1 Gene

The SMARCB1 gene, located on chromosome 22, provides instructions for creating a protein known as SMARCB1, INI1, or BAF47. This protein serves as a critical component of the SWI/SNF chromatin remodeling complex. This complex is responsible for regulating gene expression by modifying the structure of chromatin, the combination of DNA and proteins that packages genetic material into chromosomes. By controlling how DNA is accessed and read, the SMARCB1 protein acts as a tumor suppressor, helping to regulate cell growth and division. When the SMARCB1 protein is absent or dysfunctional, cells may lose their ability to control growth properly, which can lead to the development of tumors. Research indicates that the loss of this protein is a hallmark of several rare tumor types, including atypical teratoid/rhabdoid tumors.

What is rs1060503015?

The identifier rs1060503015 refers to a specific single nucleotide variant (SNP) within the SMARCB1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. Because this variant is located within a gene that functions as a tumor suppressor, researchers monitor it for potential impacts on protein function. Variants in SMARCB1 are generally categorized by how they affect the resulting protein, with some causing a complete loss of function and others leading to reduced activity. The clinical significance of any specific variant depends on whether it disrupts the protein's ability to regulate chromatin remodeling. While many SMARCB1 variants are linked to hereditary syndromes, the specific impact of rs1060503015 is categorized as having limited evidence in current clinical databases, meaning more research is required to fully understand its specific biological consequences.

Associations and Clinical Evidence

The SMARCB1 gene is primarily associated with Rhabdoid Tumor Predisposition Syndrome 1 (RTPS1), a condition characterized by an increased risk of developing rhabdoid tumors in the central nervous system and other parts of the body. Individuals with pathogenic germline variants in this gene may have a higher susceptibility to these tumors. Additionally, SMARCB1 variants have been linked to schwannomatosis and Coffin-Siris syndrome, depending on the nature and location of the genetic change. It is important to note that the presence of a variant does not guarantee the development of a tumor; some individuals with these variants never develop symptoms, a phenomenon known as reduced penetrance. Because the evidence for rs1060503015 is currently limited, it is not always clear how this specific variant contributes to disease risk compared to well-characterized pathogenic mutations.

Population Frequency and Interpretation

The rs1060503015 variant is classified as very rare in the general population. In genetic research, variants that are extremely uncommon are often scrutinized more closely because they are less likely to be benign background noise and more likely to have functional consequences. Because this variant is so rare, large-scale population studies have limited data on its distribution across different ancestral groups. When interpreting genetic information, it is essential to understand that rare variants require careful clinical correlation. If you have received information about this variant through genetic testing, it is important to discuss the findings with a genetic counselor or a medical professional. They can provide context based on your personal and family medical history, as genetic results should never be interpreted in isolation or used to make medical decisions without expert clinical guidance.

Frequently asked questions

Sources & further reading

Related variants in SMARCB1